luminal vet
desitin arzneimittel gmbh (3000816) - phenobarbital - tablette - phenobarbital (00255) 100 milligramm - hund
luminaletten vet
desitin arzneimittel gmbh (3000816) - phenobarbital - tablette - phenobarbital (00255) 15 milligramm - hund
reneel nt
biologische heilmittel heel gmbh (3061574) - berberis vulgaris (pot.-angaben); lytta vesicatoria (pot.-angaben); causticum hahnemanni (pot.-angaben); plumbum aceticum (pot.-angaben); aluminium oxydatum (pot.-angaben); serenoa repens (pot.-angaben) - tablette - berberis vulgaris (pot.-angaben) (01217) 15 milligramm; lytta vesicatoria (pot.-angaben) (02458) 30 milligramm; causticum hahnemanni (pot.-angaben) (01988) 60 milligramm; plumbum aceticum (pot.-angaben) (03077) 30 milligramm; aluminium oxydatum (pot.-angaben) (02351) 75 milligramm; serenoa repens (pot.-angaben) (03049) 30 milligramm
eusaprim infusionslösungskonzentrat konzentrat zur herstellung einer infusionslösung
glaxosmithkline gmbh & co. kg - trimethoprim, sulfamethoxazol - konzentrat zur herstellung einer infusionslösung - trimethoprim 80.mg; sulfamethoxazol 400.mg
eusaprim i.m. injektionslösung
wellcome gmbh - trimethoprim, sulfamethoxazol - injektionslösung - trimethoprim 160.mg; sulfamethoxazol 800.mg
nexpovio
stemline therapeutics b.v. - selinexor - multiples myelom - antineoplastische mittel - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
tarivid i.v 400mg
sanofi-aventis deutschland gmbh (8030868) - ofloxacinhydrochlorid - infusionslösung - ofloxacinhydrochlorid (24860) 440 milligramm
tarivid i.v. 100mg
sanofi-aventis deutschland gmbh (8030868) - ofloxacinhydrochlorid - infusionslösung - ofloxacinhydrochlorid (24860) 110 milligramm
ofloxacin hoechst 200 mg i.v.
sanofi-aventis deutschland gmbh (8030868) - ofloxacinhydrochlorid - infusionslösung - teil 1 - infusionslösung; ofloxacinhydrochlorid (24860) 220 milligramm
esketamin kalceks 25 mg/ml injektions-/infusionslösung
kalceks as - esketamin hydrochlorid -